ReviewInternational journal of molecular sciences2013
Early lung cancer diagnosis by biosensors.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Nanoparticle trends and hotspots in lung cancer diagnosis from 2006-2023: a bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Hypoxic stress granules trigger immunogenic dormancy in lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Emerging Multifunctional Carbon-Nanomaterial-Based Biosensors for Cancer Diagnosis.Small science · 2024Article
- Article
- Aptamer-based rapid diagnosis for point-of-care application.Microfluidics and nanofluidics · 2023Review
- Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC).Biosensors · 2021Review
- Biomimetic Sensors to Detect Bioanalytes in Real-Life Samples Using Molecularly Imprinted Polymers: A Review.Sensors (Basel, Switzerland) · 2021Review
- Myricanol 5-fluorobenzyloxy ether regulation of survivin pathway inhibits human lung adenocarcinoma A549 cells growth in vitro.BMC complementary medicine and therapies · 2020Article
- A DNA based visual and colorimetric aggregation assay for the early growth factor receptor (EGFR) mutation by using unmodified gold nanoparticles.Mikrochimica acta · 2019Article
- MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer.Cell proliferation · 2017Review
- Screening and Biosensor-Based Approaches for Lung Cancer Detection.Sensors (Basel, Switzerland) · 2017Review
- Electrochemical aptasensor for lung cancer-related protein detection in crude blood plasma samples.Scientific reports · 2016Article
- Microfluidic-Based Multi-Organ Platforms for Drug Discovery.Micromachines · 2016Review
- Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.Journal of translational medicine · 2015Article
- Myricanol induces apoptotic cell death and anti-tumor activity in non-small cell lung carcinoma in vivo.International journal of molecular sciences · 2015Article
- The clinical performance evaluation of novel protein chips for eleven biomarkers detection and the diagnostic model study.International journal of clinical and experimental medicine · 2015Article
- Medicinal Plants and Other Living Organisms with Antitumor Potential against Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2014Review
- Clinically Significant Dysregulation ofAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer causes an extreme threat to human health, and the mortality rate due to lung cancer has not decreased during the last decade. Prognosis or early diagnosis could help reduce the mortality rate. If microRNA and tumor-associated antigens (TAAs), as well as the corresponding autoantibodies, can be detected prior to clinical diagnosis, such high sensitivity of biosensors makes the early diagnosis and prognosis of cancer realizable. This review provides an overview of tumor-associated biomarker identifying methods and the biosensor technology available today. Laboratorial researches utilizing biosensors for early lung cancer diagnosis will be highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.